08/12/2026
A meaningful milestone for a program that started at VeriSIM Life.
PulmoSIM Therapeutics has received a U.S. Notice of Allowance for a foundational patent covering PT001, a first-in-class inhaled therapy for pulmonary hypertension and other serious pulmonary diseases.
PT001 was designed using our BIOiSIM® platform, bringing together mechanistic biology and AI to make better decisions about efficacy, safety, and human translation.
Seeing a program move from computational design to promising preclinical results, and now toward the clinic, is exactly why we built BIOiSIM.
Congratulations to the PulmoSIM team. Excited for what comes next!
Read the press release: https://na2.hubs.ly/H078dl40
